Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free BHST Stock Alerts

BioHarvest Sciences (BHST) Financials

BioHarvest Sciences logo
$2.00 +0.08 (+4.17%)
As of 02:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BioHarvest Sciences

Annual Income Statements for BioHarvest Sciences

This table shows BioHarvest Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -13 -11
Consolidated Net Income / (Loss)		 -13 -13 -11
Net Income / (Loss) Continuing Operations		 -13 -13 -11
Total Pre-Tax Income 		-13 -13 -11
Total Operating Income		 -9.97 -6.99 -5.58
Total Gross Profit		 5.63 14 20
Total Revenue		 13 25 35
Operating Revenue		 13 25 35
Total Cost of Revenue		 7.04 11 14
Operating Cost of Revenue		 7.04 11 14
Total Operating Expenses		 16 21 26
Selling, General & Admin Expense		 12 16 21
Research & Development Expense		 3.37 4.80 5.31
Total Other Income / (Expense), net		 -2.60 -5.92 -5.48
Other Income / (Expense), net		 -2.60 -5.92 -5.48
Income Tax Expense		 0.00 -0.01 -0.08
Basic Earnings per Share		 ($0.93) ($0.80) ($0.60)
Weighted Average Basic Shares Outstanding		 13.53M 16.19M 18.41M
Weighted Average Diluted Shares Outstanding		 - 17.33M 22.67M
Weighted Average Basic & Diluted Shares Outstanding		 - 17.33M 22.67M

Quarterly Income Statements for BioHarvest Sciences

No quarterly income statements for BioHarvest Sciences are available.

Annual Cash Flow Statements for BioHarvest Sciences

This table details how cash moves in and out of BioHarvest Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.09 -2.93 26
Net Cash From Operating Activities		 -8.52 -6.68 -7.23
Net Cash From Continuing Operating Activities		 -7.99 -6.68 -7.23
Net Income / (Loss) Continuing Operations		 -13 -13 -11
Consolidated Net Income / (Loss)		 -13 -13 -11
Depreciation Expense		 0.84 1.25 1.62
Non-Cash Adjustments To Reconcile Net Income		 2.98 5.53 4.23
Changes in Operating Assets and Liabilities, net		 0.76 -0.56 -1.94
Net Cash From Investing Activities		 -1.47 -3.03 -2.37
Net Cash From Continuing Investing Activities		 -1.47 -3.03 -2.37
Purchase of Property, Plant & Equipment		 -1.47 -2.84 -2.36
Other Investing Activities, net		 0.00 -0.19 -0.01
Net Cash From Financing Activities		 14 6.78 30
Net Cash From Continuing Financing Activities		 14 6.88 36
Repayment of Debt		 -0.36 -1.27 -1.38
Issuance of Debt		 14 7.75 12
Issuance of Common Equity		 0.00 0.00 18
Other Financing Activities, net		 0.40 0.41 6.68
Cash Income Taxes Paid		 - 0.05 0.04

Quarterly Cash Flow Statements for BioHarvest Sciences

No quarterly cash flow statements for BioHarvest Sciences are available.

Annual Balance Sheets for BioHarvest Sciences

This table presents BioHarvest Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 25 48
Total Current Assets		 9.05 7.86 31
Cash & Equivalents		 5.36 2.39 23
Note & Lease Receivable		 0.42 0.70 0.94
Accounts Receivable		 0.81 1.12 1.98
Inventories, net		 2.47 3.66 4.56
Plant, Property, & Equipment, net		 3.93 7.75 8.33
Total Noncurrent Assets		 2.02 9.40 8.84
Other Noncurrent Operating Assets		 2.02 9.40 8.84
Total Liabilities & Shareholders' Equity		 15 25 48
Total Liabilities		 30 24 20
Total Current Liabilities		 26 14 7.68
Short-Term Debt		 21 3.91 0.15
Accounts Payable		 3.85 7.13 4.80
Accrued Expenses		 0.46 0.40 0.39
Current Deferred Revenue		 0.72 0.91 0.49
Other Current Liabilities		 0.91 1.91 1.86
Total Noncurrent Liabilities		 3.39 9.41 12
Other Noncurrent Operating Liabilities		 3.39 9.41 12
Total Equity & Noncontrolling Interests		 -15 1.33 25
Total Preferred & Common Equity		 -15 1.33 25
Total Common Equity		 -15 1.33 25
Common Stock		 69 98 133
Retained Earnings		 -84 -96 -108

Quarterly Balance Sheets for BioHarvest Sciences

No quarterly balance sheets for BioHarvest Sciences are available.

Annual Metrics And Ratios for BioHarvest Sciences

This table displays calculated financial ratios and metrics derived from BioHarvest Sciences' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 - 22,666,842.00
DEI Adjusted Shares Outstanding		 0.00 - 22,666,842.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 - -0.48
Growth Metrics		 - - -
Revenue Growth		 0.00% 98.77% 37.00%
EBITDA Growth		 0.00% 0.60% 19.04%
EBIT Growth		 0.00% -2.71% 14.30%
NOPAT Growth		 0.00% 29.87% 20.23%
Net Income Growth		 0.00% -2.78% 13.77%
EPS Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% 21.57% -8.11%
Free Cash Flow Firm Growth		 0.00% 0.00% 18.39%
Invested Capital Growth		 0.00% 775.38% 75.47%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00%
Profitability Metrics		 - - -
Gross Margin		 44.45% 55.35% 59.34%
EBITDA Margin		 -92.52% -46.27% -27.34%
Operating Margin		 -78.65% -27.75% -16.16%
EBIT Margin		 -99.15% -51.23% -32.05%
Profit (Net Income) Margin		 -99.15% -51.27% -32.27%
Tax Burden Percent		 100.00% 100.06% 100.69%
Interest Burden Percent		 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -2,146.52% -308.66% -99.59%
ROIC Less NNEP Spread (ROIC-NNEP)		 -2,183.34% -404.76% -23.22%
Return on Net Nonoperating Assets (RNNOA)		 2,231.11% 499.64% 16.43%
Return on Equity (ROE)		 84.59% 190.98% -83.17%
Cash Return on Invested Capital (CROIC)		 0.00% -467.65% -154.38%
Operating Return on Assets (OROA)		 -83.75% -64.52% -30.44%
Return on Assets (ROA)		 -83.75% -64.56% -30.65%
Return on Common Equity (ROCE)		 84.59% 190.98% -83.17%
Return on Equity Simple (ROE_SIMPLE)		 84.59% -970.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.98 -4.89 -3.90
NOPAT Margin		 -55.05% -19.42% -11.31%
Net Nonoperating Expense Percent (NNEP)		 36.82% 96.10% -76.37%
Return On Investment Capital (ROIC_SIMPLE)		 -122.82% -93.45% -15.25%
Cost of Revenue to Revenue		 55.55% 44.65% 40.66%
SG&A Expenses to Revenue		 96.51% 64.05% 60.10%
R&D to Revenue		 26.59% 19.04% 15.39%
Operating Expenses to Revenue		 123.10% 83.10% 75.49%
Earnings before Interest and Taxes (EBIT)		 -13 -13 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 -12 -9.44
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 80.52 4.62
Price to Tangible Book Value (P/TBV)		 0.00 80.52 4.62
Price to Revenue (P/Rev)		 0.00 4.25 3.41
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 38.17 18.98
Enterprise Value to Revenue (EV/Rev)		 0.00 4.31 2.75
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 -1.38 2.94 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.23 -0.71
Leverage Ratio		 -1.01 -2.96 2.71
Compound Leverage Factor		 -1.01 -2.96 2.71
Debt to Total Capital		 361.50% 74.59% 0.58%
Short-Term Debt to Total Capital		 361.50% 74.59% 0.58%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -261.50% 25.41% 99.42%
Debt to EBITDA		 -1.75 -0.34 -0.02
Net Debt to EBITDA		 -1.29 -0.13 2.42
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 -2.94 -0.80 -0.04
Net Debt to NOPAT		 -2.18 -0.31 5.86
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.00 -3.69 0.94
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 0.34 0.55 3.97
Quick Ratio		 0.25 0.29 3.38
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 0.00 -7.41 -6.05
Operating Cash Flow to CapEx		 -578.15% -235.77% -306.84%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.84 1.26 0.95
Accounts Receivable Turnover		 15.68 26.18 22.28
Inventory Turnover		 2.85 3.67 3.42
Fixed Asset Turnover		 3.23 4.31 4.29
Accounts Payable Turnover		 1.83 2.05 2.35
Days Sales Outstanding (DSO)		 23.27 13.94 16.38
Days Inventory Outstanding (DIO)		 127.87 99.33 106.83
Days Payable Outstanding (DPO)		 199.64 178.25 155.21
Cash Conversion Cycle (CCC)		 -48.49 -64.98 -32.00
Capital & Investment Metrics		 - - -
Invested Capital		 0.33 2.85 4.99
Invested Capital Turnover		 38.99 15.89 8.81
Increase / (Decrease) in Invested Capital		 0.00 2.52 2.15
Enterprise Value (EV)		 0.00 109 95
Market Capitalization		 0.00 107 118
Book Value per Share		 ($1.10) $0.08 $1.47
Tangible Book Value per Share		 ($1.10) $0.08 $1.47
Total Capital		 5.68 5.24 26
Total Debt		 21 3.91 0.15
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 15 1.52 -23
Capital Expenditures (CapEx)		 1.47 2.84 2.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.24 -4.89 -0.06
Debt-free Net Working Capital (DFNWC)		 3.12 -2.50 23
Net Working Capital (NWC)		 -17 -6.40 23
Net Nonoperating Expense (NNE)		 5.59 8.02 7.23
Net Nonoperating Obligations (NNO)		 15 1.52 -20
Total Depreciation and Amortization (D&A)		 0.84 1.25 1.62
Debt-free, Cash-free Net Working Capital to Revenue		 -17.65% -19.40% -0.17%
Debt-free Net Working Capital to Revenue		 24.61% -9.91% 66.55%
Net Working Capital to Revenue		 -137.43% -25.42% 66.12%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.80) ($0.60)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 16.19M 18.41M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 17.33M 22.67M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 17.33M 22.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.98 -4.89 -3.90
Normalized NOPAT Margin		 -55.05% -19.42% -11.31%
Pre Tax Income Margin		 -99.15% -51.23% -32.05%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioHarvest Sciences

No quarterly metrics and ratios for BioHarvest Sciences are available.


Financials Breakdown Chart

BioHarvest Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioHarvest Sciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

BioHarvest Sciences' net income appears to be on a downward trend, with a most recent value of -$11.14 million in 2025, falling from -$12.56 million in 2023. The previous period was -$12.91 million in 2024. Find out what analysts predict for BioHarvest Sciences in the coming months.

BioHarvest Sciences' total operating income in 2025 was -$5.58 million, based on the following breakdown:
  • Total Gross Profit: $20.48 million
  • Total Operating Expenses: $26.05 million

Over the last 2 years, BioHarvest Sciences' total revenue changed from $12.67 million in 2023 to $34.51 million in 2025, a change of 172.3%.

BioHarvest Sciences' total liabilities were at $19.80 million at the end of 2025, a 16.4% decrease from 2024, and a 33.7% decrease since 2023.

In the past 2 years, BioHarvest Sciences' cash and equivalents has ranged from $2.39 million in 2024 to $23.03 million in 2025, and is currently $23.03 million as of their latest financial filing in 2025.

Over the last 2 years, BioHarvest Sciences' book value per share changed from -1.10 in 2023 to 1.47 in 2025, a change of -233.8%.


Related Companies

Financial statements for NASDAQ:BHST last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel